| Literature DB >> 22086188 |
Rose A K Whelan1, Susanne Hartmann, Sebastian Rausch.
Abstract
Inflammatory bowel disease (IBD) is a chronic disease arising due to a culmination of genetic, environmental, and lifestyle-associated factors and resulting in an excessive pro-inflammatory response to bacterial populations in the gastrointestinal tract. The prevalence of IBD in developing nations is relatively low, and it has been proposed that this is directly correlated with a high incidence of helminth infections in these areas. Gastrointestinal nematodes are the most prevalent parasitic worms, and they efficiently modulate the immune system of their hosts in order to establish chronic infections. Thus, they may be capable of suppressing unrelated inflammation in disorders such as IBD. This review describes how nematodes, or their products, suppress innate and adaptive pro-inflammatory immune responses and how the mechanisms involved in the induction of anti-nematode responses regulate colitis in experimental models and clinical trials with IBD patients. We also discuss how refinement of nematode-derived therapies should ultimately result in the development of potent new therapeutics of clinical inflammatory disorders.Entities:
Mesh:
Year: 2011 PMID: 22086188 PMCID: PMC3459088 DOI: 10.1007/s00709-011-0342-x
Source DB: PubMed Journal: Protoplasma ISSN: 0033-183X Impact factor: 3.356
Overview of murine nematode infection models applied in the context of IBD
| Organism | Model relevance | Location of infection | Th2-inducing capacity | Infection persistence |
|---|---|---|---|---|
|
| Chonic human intestinal nematode infections | Proximal small intestine, transiently tissue penetrating (L4), adults reside in lumen | ++, highly polarized | Chronic infection in most mouse strains for weeks/months |
|
| Human whipworm infections | Caecum and upper colon, intraepithelial with distal end in lumen | +/++, strongly dependent on mouse strain | Depends on infective dose and mouse strain, mostly expelled within 3 weeks |
|
| Infective to broad spectrum of mammals | Intraepithelial in small intestine, newborn infective larvae migrate into muscle tissue | ++ | Rodents expel adults within 2 weeks; long survival of infective L3 in muscle tissue |
Fig. 1A schematic overview of mechanisms suppressive to IBD conducted by intestinal nematodes. In susceptible individuals, environmental factors or genetic predisposition provokes damage to the epithelial barrier of the intestine and lead to a mucosal immune response, with macrophages producing high amounts of pro-inflammatory cytokines (TNF-α and others) and tissue-destructive effector molecules (NO, ROS). The lost integrity of the epithelial cell barrier and insufficient mucus layer facilitate bacterial translocation to subepithelial regions. DCs are activated after recognition of bacterial components and migrate to the gut-draining mLN, where they prime naïve T cells and produce IL-12/23, leading to CD4+ T cell differentiation into Th1 and Th17 cells. These migrate to the intestine and perpetuate the inflammatory response, e.g., via IFN-γ production which supports the activation of macrophages. On the contrary, DC activated via molecules released from nematodes will prime Th2 cells producing IL-4/-13. Tissue-derived cytokines like TSLP and IL-25 support the development of the Th2 response and suppress pro-inflammatory responses by DC and macrophages. The Th2 response counterbalances the activation and outgrowth on the opposing Th populations. IL-4/13 leads to the development of macrophages with an alternatively activated phenotype (AAM) expressing factors like arginase and RELM-α needed for wound repair. IL-4/13 also leads to an increased turnover of epithelial cells, hyperplasia of goblet cells, and increased mucus production. IL-22-producing Th cells may increase epithelial integrity. ES products from the nematodes directly modulate DC, suppressing their expression of MHCII, costimulatory molecules, and production of Th1- and Th17-supportive cytokines (see inlay). Certain nematode species directly favor the induction of Foxp3+ regulatory T cells via secretion of a mimic to TGF-β. DCs with a tolerogenic phenotype (e.g., production of IL-10) accumulate in mLN and support the production of IL-10 by T cells and the outgrowth of Treg populations. Tregs limit the activation and effector function of Th1 and Th17 as well as Th2 cells. AAM alternatively activated macrophage, CAM classically activated macrophage, DC dendritic cell, EC epithelial cell, E/S excretory/secretory components, IFN-γ interferon-γ, IL interleukin, mLN gut-draining mesenteric lymph nodes, NO nitric oxide, RELM-α resistin-like molecule-α, ROS reactive oxygen species, TGF-β transforming growth factor-β, Th helper T cell, TNF-α tumor necrosis factor-α, Treg regulatory T cell, TSLP thymic stromal lymphopoietin
Overview of studies assessing the therapeutic effects of nematode infections and nematode-derived components in murine colitis models
| Citation | Nematode infection model | IBD model | Form of therapy | Analyzed parameters | Proposed mechanism |
|---|---|---|---|---|---|
| Elliott et al. |
| IL-10−/− mice | Curative | ↑ IL-13, Foxp3 expression | Inhibition via induction of suppressive T cells and Th2 induction. Protection can be transferred with T cells from worm-infected donors. |
| ↓ IL-12, IFN-γ, inflammatory score | |||||
| Metwali et al. |
| IL-10−/− T cell transfer to RAG−/− mice | Curative | ↓ histological inflammation score | CD8+ Tregs required for reversal of colitis, those act independently of IL-10 or TGF-β signaling. |
| Setiawan et al. |
| TNBS | Preventative | ↑ IL-4, IL-5, IL-10, IL-13 | IL-10-dependent inhibition of pro-inflammatory cytokines and disease. IL-10R blockade in vitro restores IFN-γ and IL-12p40 production by mucosal cells. |
| ↓ IL-12p40, IFN-γ, inflammatory score | |||||
| Elliott et al. |
| IL-10−/− mice | Curative | ↓ IL-17, inflammatory score |
|
| Sutton et al. |
| TNBS | Preventative | ↑ IL-4, IL-13, mucosal mast cells and resistance | Reduced Th1 cytokine expression, protection may involve control of intestinal secretory function through mast cell-mediated mechanisms. |
| ↓ IFN-γ, TNF-α inflammatory score | |||||
| Hang et al. |
| IL-10−/− T cell transfer to RAG−/− mice | Preventative | ↑ plasmacytoid Ag, CD40 on DCs | Phenotypical changes of DC correlate with protection. Modulation of innate immune cells is sufficient to suppress colitis weeks after abrogation of |
| ↓CD80 and CD86 on DCs | |||||
| ↓ IFN-γ, IL-17, inflammatory score | |||||
| Khan et al. |
| DNBS | Preventative | ↑ IL-4, IL-13 | Decrease in colitis severity correlated with the induction of a Th2 response. |
| ↓ MPO activity, IL-12, IFN-γ, inflammatory score | |||||
| Wilson et al. |
| IL-10−/− mice | Not applicable | ↑ IL-13Rα2 (IL-13 decoy receptor), IFN-γ, IL-17, inflammation |
|
| ↓ IL-13 bioreactivity | |||||
| Nematode component | |||||
| Motomura et al. |
| DNBS | Preventative | ↑ IL-13, TGF-β | Attenuation of colitis attributed to induction of Th2 and regulatory mechanisms via nematode antigens in the absence of live worm infection. |
| ↓ MPO activity, IL-12, IFN-γ, iNOS, inflammatory score | |||||
| Du et al. |
| TNBS | Preventative | ↑ IL-4, IL-13, IL-10, TGF-β, AAM | Amelioration of colitis due to induction of Th2 and regulatory response; may involve induction of AAM. |
| ↓ inflammatory score, IFN-γ, TNF-α, IL-6, | |||||
| Schnoeller et al. |
| DSS | Concomitant with DSS application | ↓ intestinal inflammatory index, (cell infiltration, goblet cell depletion, epithelial damage, crypt loss) | Amelioration of colitis by a nematode protein also capable of attenuating Th2-driven airway inflammation. |
| Cho et al. |
| DSS | Preventative | ↑ IL-10, TGF-β, Treg | Lower inflammatory cytokine production and higher Treg frequencies correlate with protection. |
| ↓ IFN-γ, IL-6, IL-13, weight loss, inflammatory score | |||||
| Ruyssers et al. |
| TNBS | Curative | ↓ MPO activity, inflammatory score | Dose-dependent decrease of intestinal inflammation and MPO activity after treatment with ES. |
| Cancado et al. |
| DSS | Concomitant with DSS application | ↓ Th1 and Th17 cytokines, MPO and eosinophil peroxidase activity, inflammatory score | Live worms not required; both crude extracts and ES products ameliorate the disease. |
Overview of live nematode therapies studied in human clinical trials with IBD patients
| Citation | Organism | Patients | Treatment method | Clinical outcome |
|---|---|---|---|---|
| Summers et al. |
| 4 active CD patients | 2,500 ova 1×/2week | 6/7 patients reached remission after therapy; however, relapse was common within 12 weeks. Maintenance therapy with |
| 3 active UC patients | 12 weeks total | |||
| Summers et al. |
| 29 active CD patients | 2,500 | Extension of previous maintenance study. At 24 weeks, 80% of the patients had responded, and 73% were in remission. No placebo control included. |
| 24 weeks total | ||||
| Croese et al. |
| 5 inactive CD patients | Inoculation with 25–100 infective larva. Three patients re-inoculated at week 27–30 | Effects on CD activity index unclear due to low number of patients and variability in |
| 4 active CD patients | ||||
| Broadhurst et al. |
| 1 UC patient refractory to conventional treatment | Patient ingested 500 ova and 1,000 more ova 3 months later | Initial 2 doses resulted in chronic infection and remission for 3 years. Another dose was taken after relapse, and subsequent remission was correlated with an increase in IL-22-producing T cells and a decrease in IL-17 and IL-13Rα2. |
| Daveson et al. |
| 10 celiac patients in hookworm treatment and | Treatment included inoculation with 10 infective larva at week 0 and again with 5 larva at week 12 | 5 of the treatment patients experienced painful enteritis in the |
| 10 patients in saline control group |
Patient characterization, treatment method, and clinical outcome are summarized